The British Menopause Society Council aims to aid health professionals to inform and advise women about post reproductive health. Osteoporosis affects one in three women. This guidance regarding estrogen and non-estrogen-based treatments for osteoporosis responds to the controversies about the benefits and risks of individual agents. Treatment choice should be based on up-to-date evidence-based information and targeted to individual women’s needs.
National Institute for Health and Care Excellence. Osteoporosis: assessing the risk of clinical fracture: Clinical Guideline (CG146). August 2012.
2.
MansonJEChlebowskiRTStefanickMLet al .
Menopausal hormone therapy and health outcomes during the interventions and postintervention and extended poststopping phases of the Women’s Health Initiative randomized trials.JAMA2013;
310: 1353–1368.
3.
LufkinEGWahnerHWO'FallonWMet al.
Treatment of postmenopausal osteoporosis with transdermal estrogen.Ann Int Med1992;
117: 1–9.
4.
LeesB andStevensonJC.The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17β and dydrogesterone.Osteoporous Int2001;
12: 251–258.
5.
BaggerYZTankóLBAlexandersenPet al.
Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study.Bone2004;
34: 728–735.
6.
Committee on Safety of Medicines. Further advice on safety of HRT: risk: benefit unfavourable for first-line use in prevention of osteoporosis. CEM/CMO/2003/19. www.mhra.gov.uk.
7.
StevensonJC on behalf of the International Consensus Group on HRT and Regulatory Issues. HRT, osteoporosis and regulatory authorities Quis custodiet ipsos custodes? Hum Reprod 2006; 21: 1668–1671.
8.
LoboRAPickarJHStevensonJCet al.
Back to the future: hormone replacement therapy as part of a prevention strategy for women at the onset of menopause.Atherosclerosis2016;
254: 282–290.
9.
PanayNHamodaHAryaRet al.
The 2013 British Menopause Society & Women’s Health Concern recommendations on hormone replacement therapy.Menopause Int2013;
19: 59–68
10.
JansenJPBergmanGJHuelsJet al.
The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis.Semin Arthritis Rheum2011;
40: 275–284.
11.
AnagnostisPG andStevensonJC.Bisphosphonate drug holidays - when, why and for how long?Climacteric2015;
18: 32–38.
12.
ShaneEBurrDEbelingPRet al.
Atypical subtrochanteric and diaphyseal femoral fractures: a second report of a task force of the American Society for Bone and Mineral Research.J Bone Miner Res2014;
29: 1–23.
13.
BlackDMSchwartzAVEnsrudKEet al;
FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.JAMA2006;
296: 2927–2938.
14.
SilvermanSLWattsNBDelmasPDet al.
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study.Osteoporosis Int2007;
18: 25–34.
15.
Di MunnoOSeddieAD.Efficacy of ibandronate: a long term confirmation.Clin Cases Miner Bone Metab2010;
7: 23–26.
16.
BlackDMReidIRCauleyJAet al.
The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT).J Bone Miner Res2015;
30: 934–944.
17.
CummingsSRSan MartinJMcClungMRet al.
Denosumab for prevention of fractures in postmenopausal women with osteoporosis.N Engl J Med2009;
361: 756–765.
18.
TsourdiELangdahlBCohen-SolalMet al.
Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS.Bone2017;
105: 11–17.
19.
Barrett-ConnorEMoscaLCollinsPet al.Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.N Engl J Med2006;
355: 125–137.
20.
VogelVGCostantinoJPWickerhamDLet al.
National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.JAMA2006;
295: 2727–2741.
21.
NeerRMArnaudCDZanchettaJRet al.
Effect of parathyroid hormone on vertebral bone mass and fracture incidence among postmenopausal women with osteoporosis.N Engl J Med2001;
344: 1434–1441.
22.
ZhaoJ-GZengX-TWangJet al.
Association between calcium or vitamin D supplementation and fracture incidence in community-dwelling older adults. A systematic review and meta-analysis.JAMA2017;
318: 2466–2482.
23.
CanoAChedrauiPGoulisDGet al.
Calcium in the prevention of postmenopausal osteoporosis: EMAS clinical guide.Maturitas2018;
107: 7–12.
24.
JacksonRDLaCroixAZGassMet al.
Women’s Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of fractures.N Engl J Med2006;
354: 669–683.
25.
HoweTESheaBDawsonLJet al.Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev2011;
7: CD000333.
26.
SilvaRBEslickGD andDuqueD.Exercise for falls and fracture prevention in long term care facilities: a systematic review and meta-analysis.JAMDA2013;
14: 685–689.
